Please login to the form below
epigenetics
This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.
MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals
German biopharma company MorphoSys has announced that it will acquire Constellations Pharmaceuticals, a clinical-stage company with expertise in epigenetics, for a total of $1.7bn. ... We are proud that MorphoSys has recognised the strength of our team,
Latest news
-
UK scientists begin testing BCG vaccine for severe COVID-19 protection
In the same article, the authors added that the BCG vaccine induces metabolic and epigenetic changes that enhance innate immune response to subsequent infections in a process called ‘trained immunity’.
-
BMS’ oral maintenance therapy boosts survival in AML patients
We are extremely encouraged by the results of the QUAZAR AML-001 study as a part of our continuing commitment to both epigenetic research and myeloid diseases,” said Samit Hariwat, chief
-
RNA-focused biotech Storm Therapeutics raises extra £14m
First set up in 2015 by epigenetics and RNA specialists Professor Tony Kouzarides and Professor Eric Miska, the Cambridge-based company has a pipeline of early-stage molecules in development in ... world-leading company harnessing the power of RNA
-
Researchers reverse Alzheimer’s memory loss in mice
The Buffalo researchers believe their work in the developing science of epigenetics will yield answers in the elusive search for new Alzheimer's therapies. ... The researchers found that the loss of glutamate receptors resulted from an epigenetic process
-
GSK: we won’t be splitting up any time soon
Particularly in the spotlight is oncology, where GSK has cell therapy candidates, epigenetic modulators and antibodies targeting immune cells.
More from news
Approximately 1 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
The expansion of Alzheimer’s R&D is underpinned by evidence that the disease has a range of drivers, including Abeta, inflammation and epigenetics, that evolve as it progresses. ... And a host of other academic and industry teams are looking at
-
Deal Watch November 2016
licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.
-
Deal Watch January 2016
Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research
-
Deal Watch October 2015
Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).
-
Pharma deals in August 2015
This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
ICR appoints Kristian Helin as its new chief executive
Epigenetics Research.
-
Professor Thomas Cech joins Storm Therapeutics
mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.
-
Storm Therapeutics bolsters its team
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,
-
Storm Therapeutics strengthens its board
RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.
-
Rubius Therapeutics strengthens senior team
He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing
More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Omicron rise prompts tougher measures in England
- Pfizer/BioNTech promote booster against Omicron
- What is EVID AI?
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- AstraZeneca and Ionis sign $3.6bn deal for eplontersen
- Roche’s Actemra approved for severe COVID-19 in Europe
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Sanofi to buy acne specialist Origimm
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Promoting off-label use: where to draw the line?
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- ...
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
